Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, randomized, placebo-controlled, dose-ranging study of NPM-139 (semaglutide NanoPortal implant) on weight management in obese or overweight subjects

Next Previous
Trial Profile

A Phase 2, randomized, placebo-controlled, dose-ranging study of NPM-139 (semaglutide NanoPortal implant) on weight management in obese or overweight subjects

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use

Most Recent Events

  • 29 Oct 2025 New trial record
  • 04 Sep 2025 According to a Vivani Medical media release, preparations for this study will occur in parallel with Phase 1 study.
  • 04 Sep 2025 According to a Vivani Medical media release, this study will provide safety, efficacy, and dose selection information for Phase 3 and will initiate shortly after Phase 1 completes, if warranted by the Phase 1 results and pending regulatory clearance.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top